Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)

NCT00299507 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT00299507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)
Lead sponsor
Alcon Research
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
April 30, 2008
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration